I doubt that they would continue to fund it if it was a fizzer, that would stuff their personal reputations. He was just cautious as he would have to as there is some way to go with it.
What were you expecting for this phase ....absolutely brilliant results resulting in an SP rocketing to over a buck......get real!
The company will grow on the real stuff it has as if that is not good enough and good fiscal management and not on some wacked idea that we have developed a super drug.
He presented a good case for me to believe that my investment in this company will pay dividends in a few years.
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-35
-
- There are more pages in this discussion • 316 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.99 |
Change
-0.910(8.35%) |
Mkt cap ! $211.1M | |||
| Open | High | Low | Value | Volume |
| $10.50 | $10.79 | $9.30 | $1.477M | 149.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $9.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.99 | 1999 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |